Cagrisema vs tirzepatide: is the new drug actually better?

The decision you're actually facing right now

If you're researching cagrisema, you're probably weighing up whether to start tirzepatide now or hold off in case something better is around the corner. That's a reasonable thing to think about. But it's worth being clear on what cagrisema is at this stage: a combination of cagrilintide (an amylin analogue) and semaglutide, currently in late-stage clinical trials, with no regulatory approval granted in the UK, the US or Europe as of mid-2026. Novo Nordisk has published encouraging phase 3 data, but a medicine in trials is categorically different from one you can be prescribed.

Tirzepatide, by contrast, has been through the full MHRA licensing process, is recommended by NICE under technology appraisal TA1026, and is dispensed daily through regulated UK pharmacies. If you're looking at what the clinical evidence supports today, tirzepatide is the treatment with that backing. You can read more about how it works and who it suits on the Mounjaro overview.

The practical question is simpler than it sounds: start a licensed, studied treatment now, or wait for one that may or may not be approved, and on an unknown timeline. Most clinicians would frame that as a health decision, not a technology one.

How cagrisema and tirzepatide differ mechanically

Tirzepatide activates two receptors (GIP and GLP-1) which together reduce appetite, slow gastric emptying and help regulate blood sugar. It's the only dual-agonist currently licensed for weight management in the UK. The SURMOUNT-1 trial published in the New England Journal of Medicine reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, in a population of thousands of adults with obesity and without type 2 diabetes.

Cagrisema works on a different combination: semaglutide (a GLP-1 agonist) paired with cagrilintide, which mimics amylin, a hormone that signals satiety separately from the GLP-1 pathway. In theory, engaging three complementary pathways rather than two could produce stronger appetite suppression. Phase 3 REDEFINE trial data released by Novo Nordisk in early 2025 reported weight reductions of roughly 22–25% at 72 weeks, which would edge above tirzepatide's SURMOUNT-1 figures. Those numbers are not yet peer-reviewed in final published form, and cross-trial comparisons carry well-known limitations, participant selection, baseline BMI and background lifestyle support all vary between studies.

There is no head-to-head randomised controlled trial of cagrisema against tirzepatide. Without one, any claim that cagrisema is definitively better rests on cross-study arithmetic rather than controlled evidence. For context on what proper head-to-head data looks like, the wider 'better than tirzepatide' comparison page covers the SURMOUNT-5 findings.

A quick table of where things stand today

One thing you can do in under a minute: check whether any pharmacy offering you cagrisema now appears on the GPhC pharmacy register. If they're offering it for weight management, that itself is a red flag, there is no legal route to prescribe an unlicensed medicine for routine weight management through a standard online pharmacy.

What this means for choosing a treatment

If cagrisema is approved and shows a genuine efficacy advantage in the final peer-reviewed data, that matters, and it would be worth a clinical conversation at that point. But waiting for a medicine that has no approval date, and may yet face a regulatory question, means months or years without any treatment. For most people, that cost is real and worth naming plainly.

Tirzepatide is available, studied, NICE-recommended and dispensed through regulated UK pharmacies right now. For people exploring alternatives in the same pipeline, the retatrutide comparison is another option worth reading, retatrutide targets three receptors and is also still in trials. If you're also weighing up whether liraglutide holds up against tirzepatide on outcomes, that comparison page sets out what the evidence shows across both treatments. There's also a broader look at what's actually better than Mounjaro in terms of current and emerging evidence.

Side effects are part of the decision too. Tirzepatide's profile is well documented: nausea, loose stools, constipation and indigestion are the most common, particularly after starting or a dose increase, and tend to settle within a couple of weeks for most people. Cagrisema's tolerability data from trials suggests a broadly similar GI pattern, with nausea prominent, though the full picture will only emerge post-approval. If you're uncertain about the distinction between the branded and generic forms of this treatment, our page on tirzepatide versus Mounjaro explains what actually differs between them. The NHS tirzepatide medicines page sets out the current known side-effect list in plain language.

Which of these medicines (or any medicine) suits you is a clinical decision. It depends on your health history, your BMI, any conditions you have, and what your prescriber can see in front of them. Our prescribers at nume make that assessment with you, not for you. If you'd like to talk through where tirzepatide fits for you specifically, speak to our prescribers through a free consultation, same-day clinical review, no waiting list.